If you want to strengthen your income portfolio this month with some new additions, then it could be worth looking at the ASX dividend shares listed below that brokers rate as buys.
Here's what they are forecasting from them:
Dexus Industria REIT (ASX: DXI)
The team at Morgans believes that Dexus Industria could be an ASX dividend share to buy.
It is a real estate investment trust primarily invested in high quality industrial warehouses located across Sydney, Melbourne, Brisbane, Perth, and Adelaide.
The broker believes its portfolio will underpin dividends per share of 16.4 cents in FY 2024 and 16.6 cents in FY 2025. Based on the current Dexus Industria share price of $2.78, this will mean dividend yields of 5.9% and 6%, respectively.
Morgans currently has an add rating and $3.18 price target on its shares.
Macquarie Group Ltd (ASX: MQG)
Another ASX dividend share that brokers are positive on is investment bank Macquarie.
While Morgan Stanley is expecting a relatively tough year in FY 2024, it is feeling upbeat about the company's medium term outlook.
As for dividends, the broker is forecasting partially franked dividends of $6.45 per share in FY 2024 and $6.75 per share in FY 2025. Based on the current Macquarie share price of $188.33, this will mean yields of 3.4% and 3.6%, respectively.
Morgan Stanley has an overweight rating and $202.00 price target on the company's shares.
NIB Holdings Limited (ASX: NHF)
Analysts at Goldman Sachs think that NIB could be an ASX dividend share to buy.
It is an Australian health insurance company providing health and medical insurance to over one million Australian residents.
The broker thinks it could be a good option as it "offers defensive exposure to the private health insurance sector which is experiencing favourable operating trend."
In respect to income, the broker is expecting the private health giant to pay fully franked dividends per share of 29 cents in FY 2024 and 33 cents in FY 2025. Based on the current NIB share price of $7.98, this will mean 3.6% and 4.1%, respectively.
Goldman currently has a buy rating and $8.40 price target on its shares.
